KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Acquisitions: 2018-2021

Historic Acquisitions for Amneal Pharmaceuticals (AMRX) over the last 1 years, with Dec 2021 value amounting to $72.7 million.

  • Amneal Pharmaceuticals' Acquisitions was N/A to $72.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $144.3 million, marking a year-over-year change of. This contributed to the annual value of $84.7 million for FY2022, which is 42.19% down from last year.
  • Amneal Pharmaceuticals' Acquisitions amounted to $72.7 million in Q4 2021, which was down 1.51% from $73.8 million recorded in Q2 2021.
  • In the past 5 years, Amneal Pharmaceuticals' Acquisitions ranged from a high of $253.6 million in Q1 2020 and a low of -$2.6 million during Q3 2020.
  • Its 2-year average for Acquisitions is $79.6 million, with a median of $72.7 million in 2021.
  • Data for Amneal Pharmaceuticals' Acquisitions shows a peak YoY spiked of 19,587.47% (in 2021) over the last 5 years.
  • Amneal Pharmaceuticals' Acquisitions (Quarterly) stood at $3.3 million in 2018, then reached -$2.6 million in 2020, then surged by 19,587.47% to $72.7 million in 2021.
  • Its Acquisitions stands at $72.7 million for Q4 2021, versus $73.8 million for Q2 2021 and -$2.6 million for Q3 2020.